0001651308-20-000070.txt : 20200615 0001651308-20-000070.hdr.sgml : 20200615 20200615161421 ACCESSION NUMBER: 0001651308-20-000070 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20200612 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20200615 DATE AS OF CHANGE: 20200615 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BeiGene, Ltd. CENTRAL INDEX KEY: 0001651308 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 981209416 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37686 FILM NUMBER: 20963431 BUSINESS ADDRESS: STREET 1: C/O MOURANT GOVERNANCE SERVICES (CAYMAN) STREET 2: 94 SOLARIS AVENUE, CAMANA BAY CITY: GRAND CAYMAN STATE: E9 ZIP: KY1-1108 BUSINESS PHONE: 13459494123 MAIL ADDRESS: STREET 1: C/O MOURANT GOVERNANCE SERVICES (CAYMAN) STREET 2: 94 SOLARIS AVENUE, CAMANA BAY CITY: GRAND CAYMAN STATE: E9 ZIP: KY1-1108 8-K 1 a8-kx12june2020.htm 8-K Document
false0001651308 0001651308 2020-06-12 2020-06-12


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________
Form 8-K
_________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event Reported): June 12, 2020

BEIGENE, LTD.
(Exact Name of Registrant as Specified in Charter)
Cayman Islands
001-37686
98-1209416
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(I.R.S. Employer Identification Number)
c/o Mourant Governance Services (Cayman) Limited
94 Solaris Avenue, Camana Bay
Grand Cayman KY1-1108
Cayman Islands
(Address of Principal Executive Offices) (Zip Code)
+1 (345) 949-4123
(Registrant's telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
 
Trading Symbol(s)
 
Name of each exchange on which registered
American Depositary Shares, each representing 13 Ordinary Shares, par value $0.0001 per share
 
BGNE
 
The NASDAQ Global Select Market
Ordinary Shares, par value $0.0001 per share*
 
06160
 
The Stock Exchange of Hong Kong Limited
*Included in connection with the registration of the American Depositary Shares with the Securities and Exchange Commission. The ordinary shares are not registered or listed for trading in the United States but are listed for trading on The Stock Exchange of Hong Kong Limited.
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o






Item 8.01. Other Events.

On June 12, 2020, BeiGene, Ltd. (the “Company”) announced that data on its BTK inhibitor zanubrutinib in relapsed/refractory (R/R) marginal zone lymphoma (MZL) and other B-cell malignancies and its anti-PD-1 antibody tislelizumab in R/R NK/T-cell lymphomas were presented at the 25th European Hematology Association (EHA) Virtual Congress, taking place on June 11-14. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.
 
Description
99.1
 
Press release titled “BeiGene Presents Clinical Data on Zanubrutinib and Tislelizumab at the 25th European Hematology Association (EHA) Virtual Congress”, issued by the Company on June 12, 2020
104
 
The cover page from this Current Report on Form 8-K, formatted in Inline XBRL











EXHIBIT INDEX

 







SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 

BEIGENE, LTD.
 
 
 
 
 
 
Date: June 15, 2020
By:
/s/ Scott A. Samuels
 
 
Scott A. Samuels
 
 
Senior Vice President, General Counsel
 
 
 











 EX-99.1 2 a12june20pr.htm EXHIBIT 99.1 Exhibit
Exhibit 99.1
ehadatareleasefinalen_image1.jpg


BeiGene Presents Clinical Data on Zanubrutinib and Tislelizumab at the 25th European Hematology Association (EHA) Virtual Congress
CAMBRIDGE, Mass. and BEIJING, China, June 12, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that data on its BTK inhibitor zanubrutinib in relapsed/refractory (R/R) marginal zone lymphoma (MZL) and other B-cell malignancies and its anti-PD-1 antibody tislelizumab in R/R NK/T-cell lymphomas were presented at the 25th European Hematology Association (EHA) Virtual Congress, taking place on June 11-14.
“We’re pleased to share clinical results from several trials in our broad hematology development program at this year’s EHA. Zanubrutinib demonstrated encouraging efficacy and safety in multiple indications, including R/R MZL, which expands on data presented previously,” said Jane Huang, M.D., Chief Medical Officer, Hematology at BeiGene. “We look forward to receiving data from the potentially registration-enabling Phase 2 trial of zanubrutinib in R/R MZL, which has completed enrollment. ”
Phase 1/2 Study of Zanubrutinib in R/R MZL
Abstract: EP1165
Data presented at EHA were from the MZL cohort of an open-label, multicenter Phase 1/2 trial of zanubrutinib in patients with B-cell malignancies (NCT02343120). Twenty patients with R/R MZL were enrolled in this cohort, including nine with extranodal disease, five with nodal disease, and six with splenic disease.
“The high response rate observed in this study is encouraging, and zanubrutinib achieved durable responses across all subtypes. In addition, it was well tolerated among patients with R/R MZL,” commented Alessandra Tedeschi, M.D., Niguarda Cancer Center, Italy.
At the data cutoff of January 29, 2020, with a median follow-up of 27.1 months (8.3 – 51.1), 12 patients remained on study treatment. Results included:
•
The overall response rate (ORR) assessed by investigator was 80% (95% confidence interval [CI]: 56.3, 94.3), with a complete response (CR) rate of 15% and a partial response (PR) rate of 65%;
•
In patients with extranodal MZL, the ORR was 77.8% (95% CI: 40.0, 97.2), including one CR and six PRs;
•
In patients with nodal MZL, the ORR was 100% (95% CI: 47.8, 100.0), including two CRs and three PRs; and
•
In patients with splenic MZL, the ORR was 66.7% (95% CI: 22.3, 95.7), including four PRs;

1


•
The median time to response (TTR) was 2.8 months (2.6-39.6);
•
At 18 months, 66.2% of responders remained in response (95% CI: 32.4, 86);
•
The progression-free survival (PFS) rate at 24 months was 59.4% (95% CI: 33, 79);
•
The overall survival (OS) rate at 24 months was 83.2% (95% CI: 56, 94);
•
Zanubrutinib was well tolerated in patients with R/R MZL:
•
All patients experienced at least one adverse event (AE), which were primarily grade 1 or 2 in severity. The most frequently reported AEs of any grade (≥20%) include diarrhea (35%), contusion (35%), rash (35%), upper respiratory tract infection (30%), neutropenia (25%), pyrexia (25%), nasopharyngitis (20%), sinusitis (20%), nausea (20%), and fatigue (20%);
•
The most common grade ≥3 AEs (≥10%) were neutropenia (15%), anemia (10%), and pyrexia (10%);
•
Serious AEs were reported in 45% of patients (9/20); and
•
One patient discontinued treatment due to an AE and there were no deaths reported.
Biomarker Identification in R/R Non-Germinal Center B-Cell-Like (Non-GCB) Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Zanubrutinib
Abstract: EP1246
Data presented at EHA were from four clinical trials evaluating efficacy and biomarker identification of zanubrutinib in patients with R/R non-GCB DLBCL, including two trials of zanubrutinib as a monotherapy (study 1: NCT04170283; study 2: NCT03145064) and two trials of zanubrutinib in combination with an anti-CD20 antibody (study 3: NCT02569476; study 4: NCT03520920). A total of 121 patients were included in the analysis, with 79 from the monotherapy trials and 42 from the combination trials. At the data cutoff of September 9, 2019 for study 1, August 31, 2019 for study 2 and 3, and May 31, 2019 for study 4, the results included:
•
Across all four trials, the unadjusted ORR in patients with non-GCB DLBCL was similar, with an average of 29.8% (22.7-35.0); the median PFS ranged from 2.8 to 4.9 months, and the median OS ranged from 8.4 to 11.8 months;
•
In the 49 patients with GEP-confirmed activated B-cell (ABC) DLBCL classification, the ORR tended to be higher (42.9%) than non-GCB DLBCL and was comparable for monotherapy (42.1%) and combination therapy (45.5%);

2


•
In the 56 non-GCB patients with HTG gene expression profiles, PAX5 expression was higher in monotherapy responders than non-responders, and PIM1, BCL2, and FOXP1 expression was higher in combination therapy responders than non-responders;
•
Patients with double expressions of MYC and BCL2 tended to have higher ORRs (61% vs. 29%, p=0.12)) and longer PFS (5.2 months vs. 3.6 months, p=0.16) and OS (10 months vs. 7 months, p = 0.21);
•
In the 77 patients with NGS panel data, those with CD79B mutations showed significantly higher ORR than the ones without (60% vs. 26.9%, p=0.005); and
•
All three patients with NOTCH1 mutations responded to zanubrutinib monotherapy.
Zanubrutinib in Combination with Rituximab in R/R Non-Hodgkin’s Lymphoma (NHL)
Abstract: EP1271
Data presented at EHA were from a single-arm, multicenter Phase 2 trial of zanubrutinib in combination with rituximab in patients with R/R NHL (NCT03520920). A total of 41 patients were enrolled in this trial, including 20 with non-GCB DLBCL who previously received standard anthracycline ± rituximab-based treatment, 16 with follicular lymphoma (FL) who received at least one prior therapy, and five with MZL who received at least one prior therapy. At the data cutoff of August 31, 2019, with a median follow-up of 10.28 months (0.8-19.8), 14 patients remained on study treatment and the results included:
•
In patients with R/R non-GCB DLBCL,
•
The ORR as assessed by investigator per Lugano criteria 2014 was 35.0% (95% CI: 15.4, 59.2), including one (5%) CR and six (30%) PRs;
•
Median duration of response (DoR) was 8.79 months (95% CI: 0.72, 14.78);
•
Median PFS was 3.38 months (95% CI: 2.69, 5.49);
•
12-month PFS event free rate was 17.4% (95% CI: 4.3, 37.7);
•
At the time of data cutoff, two patients remained on the study treatment;
•
In patients with R/R FL,
•
The ORR as assessed by investigator per Lugano criteria 2014 was 56.3% (95% CI: 29.9, 80.2), including three (19%) CRs and six (38%) PRs;
•
Median DoR was not reached;
•
Median PFS was not estimable (NE; 95% CI: 5.49, NE);
•
12-month PFS event free rate was 66.0% (95% CI: 36.5, 84.3);

3


•
At the time of data cutoff, nine patients remained on the study treatment;
•
In patients with R/R MZL,
•
The ORR as assessed by investigator per Lugano criteria 2014 was 60.0% (95% CI: 14.7, 94.7), including one (20%) CR and two (40%) PRs;
•
Median DoR was not reached;
•
Median PFS was NE (95% CI: 11.01, NE);
•
12-month PFS event free rate was 75.0% (95% CI: 12.8, 96.1);
•
At the time of data cutoff, three patients remained on the study treatment;
•
The safety profile demonstrated in this trial for the four cohorts was consistent with previous results of zanubrutinib, including:
•
97.6% of patients experienced at least one AE, with the most common (≥10%) of any grade being decreased neutrophil count, decreased white blood cell count, anemia, upper abdominal pain, increased alanine aminotransferase, pyrexia, upper respiratory tract infection, decreased platelet count, increased aspartate aminotransferase, and purpura;
•
Grade ≥3 AEs were reported in 46.3% of patients, with the most common (≥10%) being decreased neutrophil count and decreased white blood cell count, and serious AEs were reported in 19.5% of patients;
•
Grade ≥3 infection events were reported in 9.8% of patients, and no grade ≥3 hemorrhage events were reported; and
•
Three patients with non-GCB DLBCL experienced a fatal AE, but none were reported in the FL and MZL cohorts.
Preliminary Results of Tislelizumab in R/R Extranodal NK/T-Cell Lymphoma
Abstract: EP1268
Preliminary efficacy and safety data presented at EHA were from the R/R extranodal NK/T-cell lymphoma cohort of the Phase 2 trial of tislelizumab in patients with R/R NK/T-cell neoplasms (NCT03493451). Twenty-two patients with R/R extranodal NK/T-cell lymphoma who received at least one prior systemic therapy were enrolled in this cohort and received tislelizumab (200 mg every three weeks) until disease progression, unacceptable toxicity, or end of study. At the data cutoff of October 11, 2019, six patients remained on study treatment and the results included:

4


•
The ORR assessed by investigator per Lugano criteria with LYRIC modification for immunomodulatory drugs (Cheson et al 2016) was 31.8% (95% CI: 13.9, 54.9), with a CR rate of 18.2% and a PR rate of 13.6%;
•
The median DoR had not been reached and the median TTR was 5.75 months (2.14-14.29);
•
The median PFS was 2.7 months (95%CI: 1.45, 5.32) and the median PFS follow-up duration was 11.3 months;
•
Tislelizumab was generally well-tolerated, including:
•
The most frequently reported (≥15%) treatment-emergent adverse events (TEAEs) were anemia and pyrexia (27.3%, each) and hypoalbuminemia, hyperglycemia, and hypokalemia (18.2%, each);
•
Grade ≥3 TEAEs were reported in 11 (50%) patients; anemia and neutrophil count decrease were reported in at least two patients;
•
Serious TEAEs were reported in eight (36.4%) patients, with four patients determined to be possibly related to tislelizumab;
•
Immune-related (ir) TEAEs were reported in seven (31.8%) patients;
•
One patient experienced a TEAE of grade 5 respiratory failure leading to treatment discontinuation, which was not related to tislelizumab as assessed by investigator; and
•
One patient experienced a fatal TEAE.
Preliminary Results of Tislelizumab in R/R Peripheral T-Cell Lymphomas (PTCL)
Abstract: EP1235
Preliminary efficacy and safety data presented at EHA were from the R/R PTCL cohort of the Phase 2 trial of tislelizumab in patients with R/R NK/T-cell neoplasms (NCT03493451). Forty-four patients with R/R PTCL who received at least one prior combination therapy enrolled in this cohort, including 21 patients with PTCL-not otherwise specified (PTCL-NOS), 11 patients of angioimmunoblastic T-cell lymphoma (AITL), and 12 patients with anaplastic large-cell lymphoma (ALCL). Patients received tislelizumab (200 mg every three weeks) until disease progression, unacceptable toxicity, or end of study. At the data cutoff of October 11, 2019, six patients remained on the study treatment and the results included:
•
Across all PTCL subtypes, the ORR as assessed by investigator per Lugano criteria (2014) with LYRIC modification for immunomodulatory drugs (Cheson et al 2016) was 20.5% (95% CI: 9.8, 35.3);

5


•
In patients with R/R PTCL-NOS, the ORR was 23.8% (95% CI: 8.2, 47.2), including three CRs and two PRs;
•
In patients with R/R AITL, the ORR was 18.2% (95% CI: 2.3, 51.8), including two PRs;
•
In patients with R/R ALCL, the ORR was 16.7% (95% CI: 2.1, 48.4), including two PRs;
•
Across all PTCL subtypes, the median DoR was 8.2 months (95% CI: 2.7, NE);
•
In patients with R/R PTCL-NOS, the median DoR was NE (95% CI: 2.7, NE);
•
In patients with R/R AITL, the median DoR was 3.2 months (95% CI: NE, NE);
•
In patients with R/R ALCL, the media DoR was 8.3 months (95% CI: 8.2, 8.4);
•
Across all PTCL subtypes, the median TTR was 2.9 months (95% CI: 22.1, 5.8);
•
In patients with R/R PTCL-NOS, the median TTR was 4.6 (95% CI: 2.8, 5.8);
•
In patients with R/R AITL, the median TTR was 2.5 months (95% CI: 2.1, 2.9);
•
In patients with R/R ALCL, the media TTR was 2.7 months (95% CI: 2.7, 2.7);
•
Across all PTCL subtypes, the median PFS was 2.7 months (95% CI: 2.6, 4.8);
•
In patients with R/R PTCL-NOS, the median PFS was 2.7 (95% CI: 2.2, 5.4);
•
In patients with R/R AITL, the median PFS was 3.4 months (95% CI: 1.6, 5.3);
•
In patients with R/R ALCL, the media PFS was 2.7 months (95% CI: 1.0, 10.9);
•
Tislelizumab was generally well-tolerated and the safety profile was similar to that of other anti-PD-1 antibodies, including:
•
The most frequently reported (≥10%) TEAEs were pyrexia (34.1%), asthenia and anemia (18.2%), arthralgia, cough, and thrombocytopenia (15.9%), pruritus (13.6%), and erythema, hypothyroidism, neutropenia, and upper respiratory tract infection (11.4%);
•
Grade ≥3 TEAEs were reported in 23 (52.3%) patients; neutropenia, anemia, thrombocytopenia, general physical health deterioration, pneumonia and pyrexia were reported in at least two patients;
•
Serious TEAEs were reported in 21 (47.7%) patients;
•
irTEAEs were reported in 18 (40.9%) patients, with all being Grade 1 or 2 except one event of Grade 3 erythema; and

6


•
Nine (23.7%) patients discontinued treatment due to TEAEs; and three (6.8%) patients experienced a fatal TEAE, all of which were assessed to be likely related to disease progression.
To learn more about BeiGene’s pipeline and data presented at the 25th EHA Virtual Congress, visit our virtual booth at https://beigenemedical.eu/.
About BRUKINSA® (zanubrutinib)
BRUKINSA is a small molecule inhibitor of Bruton’s tyrosine kinase (BTK) discovered by BeiGene scientists that is currently being evaluated globally in a broad pivotal clinical program as a monotherapy and in combination with other therapies to treat various B-cell malignancies.
BRUKINSA was approved by the U.S. FDA to treat adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy on November 14, 2019. This indication was approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
BRUKINSA was approved in China for the treatment of MCL in adult patients who have received at least one prior therapy and CLL or SLL in adult patients who have received at least one prior therapy in June 2020.
BRUKINSA is not approved for use outside the United States and China.
IMPORTANT U.S. SAFETY INFORMATION FOR BRUKINSA (ZANUBRUTINIB)
Warnings and Precautions
Hemorrhage
Fatal and serious hemorrhagic events have occurred in patients with hematological malignancies treated with BRUKINSA monotherapy. Grade 3 or higher bleeding events including intracranial and gastrointestinal hemorrhage, hematuria and hemothorax have been reported in 2% of patients treated with BRUKINSA monotherapy. Bleeding events of any grade, including purpura and petechiae, occurred in 50% of patients treated with BRUKINSA monotherapy.
Bleeding events have occurred in patients with and without concomitant antiplatelet or anticoagulation therapy. Co-administration of BRUKINSA with antiplatelet or anticoagulant medications may further increase the risk of hemorrhage.
Monitor for signs and symptoms of bleeding. Discontinue BRUKINSA if intracranial hemorrhage of any grade occurs. Consider the benefit-risk of withholding BRUKINSA for 3-7 days pre- and post-surgery depending upon the type of surgery and the risk of bleeding.

7


Infections
Fatal and serious infections (including bacterial, viral, or fungal) and opportunistic infections have occurred in patients with hematological malignancies treated with BRUKINSA monotherapy. Grade 3 or higher infections occurred in 23% of patients treated with BRUKINSA monotherapy. The most common Grade 3 or higher infection was pneumonia. Infections due to hepatitis B virus (HBV) reactivation have occurred.
Consider prophylaxis for herpes simplex virus, pneumocystis jiroveci pneumonia and other infections according to standard of care in patients who are at increased risk for infections. Monitor and evaluate patients for fever or other signs and symptoms of infection and treat appropriately.
Cytopenias
Grade 3 or 4 cytopenias, including neutropenia (27%), thrombocytopenia (10%), and anemia (8%) based on laboratory measurements, were reported in patients treated with BRUKINSA monotherapy.
Monitor complete blood counts during treatment and treat using growth factor or transfusions, as needed.
Second Primary Malignancies
Second primary malignancies, including non-skin carcinoma, have occurred in 9% of patients treated with BRUKINSA monotherapy. The most frequent second primary malignancy was skin cancer (basal cell carcinoma and squamous cell carcinoma of skin), reported in 6% of patients. Advise patients to use sun protection.
Cardiac Arrhythmias
Atrial fibrillation and atrial flutter have occurred in 2% of patients treated with BRUKINSA monotherapy. Patients with cardiac risk factors, hypertension, and acute infections may be at increased risk. Grade 3 or higher events were reported in 0.6% of patients treated with BRUKINSA monotherapy. Monitor signs and symptoms for atrial fibrillation and atrial flutter and manage as appropriate.
Embryo-Fetal Toxicity
Based on findings in animals, BRUKINSA can cause fetal harm when administered to a pregnant woman. Administration of zanubrutinib to pregnant rats during the period of organogenesis caused embryo-fetal toxicity, including malformations at exposures that were 5 times higher than those reported in patients at the recommended dose of 160 mg twice daily. Advise women to avoid becoming pregnant while taking BRUKINSA and for at least 1 week after the last dose. Advise men to avoid fathering a child during treatment and for at least 1

8


week after the last dose. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus.
Adverse Reactions
The most common adverse reactions in > 10% of patients who received BRUKINSA were neutrophil count decreased (53%), platelet count decreased (39%), upper respiratory tract infection (38%), white blood cell count decreased (30%), hemoglobin decreased (29%), rash (25%), bruising (23%), diarrhea (20%), cough (20%), musculoskeletal pain (19%), pneumonia (18%), urinary tract infection (13%), hematuria (12%), fatigue (11%), constipation (11%), and hemorrhage (10%). The most frequent serious adverse reactions were pneumonia (11%) and hemorrhage (5%).
Of the 118 patients with MCL treated with BRUKINSA, 8 (7%) patients discontinued treatment due to adverse reactions in the trials. The most frequent adverse reaction leading to treatment discontinuation was pneumonia (3.4%). One (0.8%) patient experienced an adverse reaction leading to dose reduction (hepatitis B).
Drug Interactions
CYP3A Inhibitors: When BRUKINSA is co-administered with a strong CYP3A inhibitor, reduce BRUKINSA dose to 80 mg once daily. For co-administration with a moderate CYP3A inhibitor, reduce BRUKINSA dose to 80 mg twice daily.
CYP3A Inducers: Avoid co-administration with moderate or strong CYP3A inducers.
Specific Populations
Hepatic Impairment:  The recommended dose of BRUKINSA for patients with severe hepatic impairment is 80 mg orally twice daily.
INDICATION
BRUKINSA is a kinase inhibitor indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
Please see full U.S. Prescribing Information at www.beigene.com/PDF/BRUKINSAUSPI.pdf and Patient Information at www.beigene.com/PDF/BRUKINSAUSPPI.pdf.
About Tislelizumab
Tislelizumab (BGB-A317) is a humanized IgG4 anti–PD-1 monoclonal antibody specifically designed to minimize binding to FcγR on macrophages. In pre-clinical studies, binding to FcγR

9


on macrophages has been shown to compromise the anti-tumor activity of PD-1 antibodies through activation of antibody-dependent macrophage-mediated killing of T effector cells. Tislelizumab is the first drug from BeiGene’s immuno-oncology biologics program and is being developed internationally as a monotherapy and in combination with other therapies for the treatment of a broad array of both solid tumor and hematologic cancers.
Tislelizumab is approved by the China National Medical Products Administration as a treatment for patients with classical Hodgkin’s lymphoma who received at least two prior therapies and for patients with locally advanced or metastatic urothelial carcinoma (UC) with PD-L1 high expression whose disease progressed during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. Additionally, the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has accepted a supplemental new drug application (sNDA) of BeiGene’s anti-PD-1 antibody tislelizumab in combination with two chemotherapy regimens for first-line treatment of patients with advanced squamous non-small cell lung cancer (NSCLC).
Currently, 15 potentially registration-enabling clinical trials are being conducted in China and globally, including 11 Phase 3 trials and four pivotal Phase 2 trials.
Tislelizumab is not approved for use outside of China.
About BeiGene
BeiGene is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative medicines to improve treatment outcomes and access for patients worldwide. Our 3,800+ employees in China, the United States, Australia, and Europe are committed to expediting the development of a diverse pipeline of novel therapeutics for cancer. We currently market or plan to market two internally-discovered oncology products: BTK inhibitor BRUKINSA® (zanubrutinib) in the United States and China, and anti-PD-1 antibody tislelizumab in China. We also market or plan to market in China additional oncology products licensed from Amgen Inc., Celgene Logistics Sàrl, a Bristol Myers Squibb (BMS) company, and EUSA Pharma. To learn more about BeiGene, please visit www.beigene.com and follow us on Twitter at @BeiGeneUSA.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding clinical data from ongoing clinical trials of zanubrutinib and tislelizumab; and continuing and further development and commercialization efforts and transactions with third parties. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeiGene's ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval;

10


BeiGene's ability to achieve commercial success for its marketed products and drug candidates, if approved; BeiGene's ability to obtain and maintain protection of intellectual property for its technology and drugs; BeiGene's reliance on third parties to conduct drug development, manufacturing and other services; BeiGene’s limited operating history and BeiGene's ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates; the impact of the COVID-19 pandemic on the Company’s clinical development, commercial and other operations, as well as those risks more fully discussed in the section entitled “Risk Factors” in BeiGene’s most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in BeiGene's subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeiGene undertakes no duty to update such information unless required by law.


Investor Contact
Craig West
+1 857-302-5189
ir@beigene.com
Media Contact
Liza Heapes or Vivian Ni
+1 857-302-5663 or +1 857-302-7596
media@beigene.com

11

 EX-101.SCH 3 bgne-20200612.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001000 - Document - Cover Document link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 4 bgne-20200612_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 5 bgne-20200612_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 6 bgne-20200612_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Street Address Entity Address, Address Line One Entity Address, Street Address 2 Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Address, Country Entity Address, Country City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Title of each class Title of 12(b) Security Trading Symbol Trading Symbol Name of each exchange on which registered Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Central Index Key Entity Central Index Key Amendment Flag Amendment Flag EX-101.PRE 7 bgne-20200612_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 8 ehadatareleasefinalen_image1.jpg begin 644 ehadatareleasefinalen_image1.jpg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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.1 html 1 95 1 false 0 0 false 0 false false R1.htm 0001000 - Document - Cover Document Sheet http://beigene.com/role/CoverDocument Cover Document Cover 1 false false All Reports Book All Reports a8-kx12june2020.htm a12june20pr.htm bgne-20200612.xsd bgne-20200612_cal.xml bgne-20200612_def.xml bgne-20200612_lab.xml bgne-20200612_pre.xml http://xbrl.sec.gov/dei/2019-01-31 true true XML 11 a8-kx12june2020_htm.xml IDEA: XBRL DOCUMENT 0001651308 2020-06-12 2020-06-12 false 0001651308 8-K 2020-06-12 BEIGENE, LTD. E9 001-37686 98-1209416 c/o Mourant Governance Services (Cayman) Limited 94 Solaris Avenue, Camana Bay Grand Cayman KY1-1108 KY 345 949-4123 false false false false American Depositary Shares, each representing 13 Ordinary Shares, par value $0.0001 per share BGNE NASDAQ false XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } ZIP 13 0001651308-20-000070-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001651308-20-000070-xbrl.zip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end XML 14 R1.htm IDEA: XBRL DOCUMENT v3.20.1
Cover Document
Jun. 12, 2020
Cover [Abstract]  
Document Type 8-K
Document Period End Date Jun. 12, 2020
Entity Registrant Name BEIGENE, LTD.
Entity Incorporation, State or Country Code E9
Entity File Number 001-37686
Entity Tax Identification Number 98-1209416
Entity Address, Street Address c/o Mourant Governance Services (Cayman) Limited
Entity Address, Street Address 2 94 Solaris Avenue, Camana Bay
Entity Address, City or Town Grand Cayman
Entity Address, Postal Zip Code KY1-1108
Entity Address, Country KY
City Area Code 345
Local Phone Number 949-4123
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of each class American Depositary Shares, each representing 13 Ordinary Shares, par value $0.0001 per share
Trading Symbol BGNE
Name of each exchange on which registered NASDAQ
Entity Emerging Growth Company false
Entity Central Index Key 0001651308
Amendment Flag false
EXCEL 15 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end JSON 17 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "a8-kx12june2020.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "calculationLink": { "local": [ "bgne-20200612_cal.xml" ] }, "definitionLink": { "local": [ "bgne-20200612_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-eedm-def-2018-01-31.xml", "http://xbrl.fasb.org/srt/2018/elts/srt-eedm1-def-2018-01-31.xml" ] }, "inline": { "local": [ "a8-kx12june2020.htm" ] }, "labelLink": { "local": [ "bgne-20200612_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "bgne-20200612_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "bgne-20200612.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2018/elts/srt-types-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-roles-2018-01-31.xsd", "http://xbrl.fasb.org/srt/2018/elts/srt-roles-2018-01-31.xsd", "http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2018/elts/us-types-2018-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "https://xbrl.sec.gov/exch/2018/exch-2018-01-31.xsd", "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "bgne", "nsuri": "http://beigene.com/20200612", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a8-kx12june2020.htm", "contextRef": "D2020Q2EHA", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001000 - Document - Cover Document", "role": "http://beigene.com/role/CoverDocument", "shortName": "Cover Document", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "a8-kx12june2020.htm", "contextRef": "D2020Q2EHA", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/CoverDocument" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/CoverDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/CoverDocument" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/CoverDocument" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Street Address" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/CoverDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Street Address 2" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/CoverDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/CoverDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country", "terseLabel": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/CoverDocument" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/CoverDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/CoverDocument" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/CoverDocument" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/CoverDocument" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/CoverDocument" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/CoverDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/CoverDocument" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/CoverDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/CoverDocument" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/CoverDocument" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of each class" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/CoverDocument" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Name of each exchange on which registered" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/CoverDocument" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/CoverDocument" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/CoverDocument" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://beigene.com/role/CoverDocument" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" }